Immunovia AB (IMMNOV) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. This is Jeff Borchening. Thank you very much for joining the call this morning. We are excited to speak with you about the fourth quarter for 2025 and what lies ahead as we continue to build on the success of the Pancreasure launch and prepare for securing reimbursement and continuing to drive the success of this product as we move to achieve our mission of changing the way we detect cancer in pancreatic cancer and making a significant difference in people's lives. For our agenda today, we will do a brief review of 2025. We'll go into more detail about the Pancreasure commercial results in the fourth quarter of the year. We'll then talk about our progress towards reimbursement with a special focus on the clinical studies that lie ahead as well as the steps that we've already accomplished. And then finally, I'll turn it over to my colleague, Adam Beckstrom, to discuss the Q4 financial results in our cash position. In 2025, more than two years of development and clinical research culminated in the commercial launch of Pancreasure. And as we look back on 2025, there are a number of things that we're proud of as a company, but here are some of the highlights. Certainly at the top of the list has to be the commercial launch of the Pancreasure test. A couple years ago, we made the difficult decision to remove our Emre Pen Candide test from the market and bring to the market a better test that could detect cancers earlier, could do it with a greater level of sensitivity and specificity, particularly for those people who don't secrete CA-19-9. We also wanted to make sure that we had a much more robust set of clinical data supporting the pancreas sure test and I think we clearly saw that in 2025 when you look at the scientific dissemination that happen...